Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Feb 27, 2023
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2023-02-23$68.76/sh−1,646$113,179→ 53,883 total
Footnotes (1)
- [F1]Sale originated from established 10b5-1 trading plan.